carboplatin + docetaxel + pertuzumab + trastuzumab + trastuzumab emtansine

This is a multi-agent combination regimen consisting of five drugs used in the treatment of HER2-positive breast cancer, particularly in the neoadjuvant and adjuvant settings. The regimen includes: - **Carboplatin** (a platinum-based chemotherapy that induces DNA crosslinking and apoptosis) - **Docetaxel** (a taxane chemotherapy that stabilizes microtubules, inhibiting cell division) - **Pertuzumab** (a monoclonal antibody targeting the HER2 receptor, preventing dimerization with other HER family members) - **Trastuzumab** (a monoclonal antibody targeting the extracellular domain IV of HER2, blocking downstream signaling and mediating antibody-dependent cellular cytotoxicity) - **Trastuzumab emtansine (T-DM1)** (an antibody-drug conjugate combining trastuzumab with DM1, a cytotoxic agent that inhibits microtubule assembly; delivers targeted cytotoxicity to HER2-expressing cells) This combination is designed to maximize anti-tumor efficacy by combining direct cytotoxic agents with dual anti-HER2 blockade and targeted delivery of chemotherapy. It is primarily investigated for high-risk or early-stage HER2-positive breast cancer as part of neoadjuvant or adjuvant therapy regimens[1][2][3][6][8].